TFF3 and ocular melanoma: A phase-II trial that evaluated the efficacy of recombinant human intestinal trefoil factor (rhITF) oral spray for prevention of OM showed the spray was safe, well tolerated, and effective in reducing the frequency and severity of OM in patients with colorectal cancer treated with chemotherapy (75).